A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Phase of Trial: Phase II
Latest Information Update: 25 Sep 2018
Price : $35 *
At a glance
- Drugs Istiratumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms CARRIE
- Sponsors Merrimack Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 25 Jun 2018 Status changed from active, no longer recruiting to discontinued, according to a Merrimack Pharmaceuticals media release.
- 25 Jun 2018 According to a Merrimack Pharmaceuticals media release, Merrimack plans to present the complete data from this Phase 2 study at an upcoming medical oncology meeting.